Efficacy and Gastrointestinal Tolerability of Oral Oxycodone/Naloxone Combination for Chronic Pain in Outpatients With Cancer: An Observational Study

Arturo Cuomo, Gennaro Russo, Gennaro Esposito, Cira Antonietta Forte, Marianna Connola, Claudio Marcassa

Research output: Contribution to journalArticle

Abstract

Combination opioid agonist/antagonist therapy has been shown to preserve bowel function in patients with chronic cancer pain. This retrospective study evaluated the efficacy and tolerability of prolonged-released fixed-dose oxycodone-naloxone (PR OXN) in consecutive outpatients with chronic cancer pain. Of 206 patients prescribed PR OXN (mean age 61.3 ± 12.9 years; 52.9% female), 31.5% were opioid naïve. PR OXN was associated with a significant decrease in pain score measured on a visual analogue scale over 28 days (P

Original languageEnglish
Pages (from-to)867-876
Number of pages10
JournalAmerican Journal of Hospice and Palliative Medicine
Volume31
Issue number8
DOIs
Publication statusPublished - Dec 10 2014

Keywords

  • advanced cancer pain
  • chronic cancer pain
  • combination therapy
  • opioid-induced constipation
  • outpatients
  • oxycodone/naloxone

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Efficacy and Gastrointestinal Tolerability of Oral Oxycodone/Naloxone Combination for Chronic Pain in Outpatients With Cancer: An Observational Study'. Together they form a unique fingerprint.

  • Cite this